"In light of the clinical success rates, significantly reduced complication rates, and reduced procedure times, our center is fully adopting this new technology," stated Dr. Murray. "Prior to this approach, our drug-free success rate in one series of 63 patients with persistent and paroxysmal AF treated by conventional catheter ablation technology was 68% with a 7% complication rate."
The second abstract authored by Dr. James and Dr. Bourke evaluated 65 patients with drug-refractory AF, of which 17 had persistent AF and 48 had paroxysmal AF. Pulmonary vein isolation (PVI) was performed, with further ablation for sites of complex fractionation, as needed (n = 31). Acute success was achieved in 64 of the 65 patients and, at a mean follow-up time of 9.1 months, 88% of patients were free of AF as measured by 7-day continuous monitoring. The mean procedure time was 165 minutes for both types of AF, which was significantly shorter than the reported 208 minutes when using conventional ablation technology.
"The PVAC catheter is a genuine advance in AF-ablation technology," stated Dr. James. "With conventional RF technology for PVI, physicians are faced with a challenging and time-consuming procedure with variable success rates. We found that with the Ablation Frontiers technology, we could achieve high acute success rates and low recurrence rates of AF with significantly shorter procedure times. Medium-term follow-up data is encouraging."
These results are similar to findings presented recently at other leading scientific sessions from several studies using Ablation Frontiers novel technology.
"We are committed to the ongoing research of our innovative AF ablation
technology and look forward to long-term results from these and other
studies," stated Keegan Harper, Chief Executive Officer of Ablation
Frontiers. "We are very grateful to the investigators and their colleagues,
who have been most diligent in
'/>"/>
| SOURCE Ablation Frontiers, Inc. Copyright©2008 PR Newswire. All rights reserved |